Regeneron Pharmaceuticals and CytomX Therapeutics have significantly expanded their strategic research and licensing collaboration, aiming to pioneer the development of…
Read More
Cellares, TScan to assess automated manufacturing of TSC-101 therapy
In a significant development poised to accelerate the accessibility of cutting-edge cell therapies, Cellares and TScan Therapeutics have announced a…
Read More
Eli Lilly and Ascidian Therapeutics Forge Strategic Alliance to Revolutionize Kidney Disease Treatment Through Advanced Genetic Medicine
Eli Lilly and Company has announced a significant research collaboration and licensing agreement with Ascidian Therapeutics, a pioneering biotechnology firm…
Read More
ASCO 2026: Navigating the Evolving Landscape of Non-Small Cell Lung Cancer with Promising Data from Eli Lilly and Mixed Reactions for Summit/Akeso
The American Society of Clinical Oncology (ASCO) 2026, held from May 29 to June 2, 2026, served as a critical…
Read More
FDA Grants Priority Review to Roche’s Giredestrant for Early-Stage Breast Cancer, Signaling Potential Paradigm Shift in Adjuvant Therapy
The US Food and Drug Administration (FDA) has accepted priority review of the new drug application (NDA) for Roche’s investigational…
Read More
European Commission Approves AbbVie’s Aquipta (atogepant) for Acute Migraine Treatment
AbbVie has secured a significant regulatory endorsement from the European Commission (EC) for Aquipta (atogepant), marking a pivotal expansion of…
Read More
Contraline Secures $92.5 Million in Series B Funding to Advance Reversible Male Contraceptive to Late-Stage Clinical Trials
Contraline, a pioneering biotechnology firm backed by Google Ventures, has successfully closed a substantial $92.5 million Series B financing round.…
Read More
ASCO 2026 Delivers Promising Advances and Crucial Data in Blood Cancer Treatment
The 2026 American Society of Clinical Oncology (ASCO) conference, a cornerstone event for oncological advancements, has concluded, leaving a significant…
Read More
Lilly’s $7bn Acquisition of Kelonia Bears Fruit as In Vivo Cell Therapies Show Significant Promise at ASCO 2026
The American Society for Clinical Oncology (ASCO) meeting in 2026, a cornerstone event for oncological advancements, has concluded, leaving behind…
Read More
ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma – Pharmaceutical Technology
The rapidly evolving landscape of multiple myeloma treatment is witnessing a pivotal moment with the emergence of in vivo chimeric…
Read MoreYOU MAY HAVE MISSED
